Sermorelin Safety for Adults Ages 30 to 49: What the Evidence Actually Shows

HealthRX.com

No sermorelin product is FDA-approved for adults

Print or save as PDF

Key numbers

  • 30 micrograms/kgStudy dose given subcutaneously at bedtime to children in the one-year program, not a recommended adult doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 2 mgNightly self-injected dose in a 6-week study of men aged 64 to 76Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 3 hoursDuration growth hormone stayed elevated after dosing in a short study of healthy adult menSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • Regulatory status / No FDA-approved sermorelin; Geref approvals withdrawn June 2009 [4]
  • What Geref covered / Pediatric growth hormone deficiency treatment and a pituitary diagnostic test only [4]
  • Data in adults 30 to 49 / No dedicated safety study; one short pharmacokinetic study enrolled healthy men aged 19 to 43 [1]
  • Largest follow-up dataset / 1 year, in 110 children [6]
  • What it is / A 29-amino-acid GHRH analogue, not growth hormone [7]
  • Sport status / Prohibited at all times by WADA, S2.2.4 [8]

Is sermorelin approved for adults aged 30 to 49?

No. Geref was approved under two applications: NDA 019863 (0.05 mg/ampule, approved December 28, 1990) for evaluating the pituitary's ability to secrete growth hormone, and NDA 020443 (0.5 mg and 1 mg vials, approved September 26, 1997) for treating idiopathic growth hormone deficiency in children with growth failure. Neither covered adults, anti-aging, weight loss or athletic performance [4].

The manufacturer discontinued both in 2008 and asked FDA to withdraw them; FDA withdrew approval effective June 18, 2009, and in March 2013 determined that Geref had not been withdrawn from sale for reasons of safety or effectiveness [4]. Sermorelin sold in the US today is compounded, and compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness or quality before they are marketed [5].

What safety data exist for adults?

One adult pharmacokinetic study enrolled 30 healthy men aged 19 to 43, an age range that reaches into the 30s, and gave the peptide intravenously or intranasally. An intravenous dose as low as 0.25 micrograms/kg raised growth hormone. Growth hormone stayed elevated for about 3 hours even though the peptide was rapidly eliminated, and three intranasal doses in a day did not suppress growth hormone secretion the following night [1]. That study measured hormone release over hours, not safety over time.

The other two adult studies enrolled men over 60. Ten healthy men with a mean age of 68 took 0.5 mg and 1 mg subcutaneously twice daily for 14 days each, and at the higher dose 24-hour growth hormone and IGF-I rose to levels not significantly different from 9 young men with a mean age of 26 [2]. Eleven men aged 64 to 76 self-injected 2 mg nightly for 6 weeks, and nocturnal growth hormone release rose while IGF-I did not change [3]. The 14-day study was a short physiology study, not a clinical-benefit trial [2]. The 6-week study did measure muscle and metabolic outcomes: two of six strength measures and one endurance test improved, while IGF-I, body composition, glucose and insulin did not change [3].

Questions worth asking

Choose the questions you want to keep

What did the one-year study show, and in whom?

The largest dataset is an open-label, multicenter, one-year study of 110 previously untreated prepubertal children with growth hormone deficiency, 86 of them evaluable, given 30 micrograms/kg subcutaneously at bedtime [6]. No adverse changes appeared in general biochemical or hormonal analyses, fasting glucose did not change, IGF-I was not excessively raised, and sermorelin was well tolerated overall [6].

A 2018 review of growth hormone secretagogues reported that available studies of this broader class generally showed good tolerability, while noting concern about increased blood glucose from reduced insulin sensitivity and limited long-term safety evidence. These findings do not establish the long-term safety of sermorelin specifically [9].

Dose for adults

No sermorelin product is currently FDA-approved, so there is no current approved dose [4]. The doses used in the studies above were study doses, not recommended adult doses: 30 micrograms/kg once daily subcutaneously at bedtime in the pediatric program, and 0.5 mg or 1 mg twice daily for 14 days in the older-men study [6][2].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, which of these uses did Geref's approvals not cover?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Is sermorelin FDA-approved for adults?
No. Geref was approved only for treating idiopathic growth hormone deficiency in children and for a pituitary diagnostic test, and those approvals were withdrawn in 2009 [4]. Sermorelin sold today is compounded and is not FDA-reviewed for safety, effectiveness or quality [5].
What side effects are known in adults aged 30 to 49?
The adult studies of sermorelin were short and none targeted this age group. A short pharmacokinetic study enrolled men aged 19 to 43, but it measured hormone responses rather than safety over time [1]. In the year-long study of 110 children, biochemistry, hormone tests and fasting glucose showed no adverse changes and IGF-I was not excessively raised [6].
Is sermorelin allowed in sport?
No. WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, prohibited at all times in and out of competition, and the 2027 List names it as well [8][10].
How long have people been followed on sermorelin?
The largest dataset followed 110 children for one year [6], and a review reports data in a few children suggesting the effect was maintained for 36 months of continued treatment [7]. The adult studies ran 14 days and 6 weeks [2][3]. A 2018 review of growth hormone secretagogues states that safety with long-term use, including cancer incidence and mortality, still needs evaluation [9].
Show all 10 referencesHide references
  1. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
  2. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
  3. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
  4. Federal Register :: Request Access.
  5. Official web page.
  6. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
  7. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
  8. World Anti-Doping Agency.
  9. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53.
  10. World Anti-Doping Agency.
Sermorelin safety: evidence summary chart
Image: HealthRX.com. Full sermorelin safety guide and sources at healthrx.com/sermorelin.